LXP Industrial REIT offers attractive Series C cumulative preferred shares with a nearly 7% yield and strong coverage from FFO. LXP maintained stable net interest expenses and robust Q3 results, with preferred dividends representing less than 5% of net income. LXP.PR.C preferreds trade at a discount to the call price, with a high conversion threshold making forced conversion unlikely in the near term.

NEW YORK--(BUSINESS WIRE)--Today Mercer, a business of Marsh McLennan (NYSE: MMC) and a global leader in helping clients realize their investment objectives, shape the future of work and enhance health and retirement outcomes for their people, released findings from its inaugural annual survey, Voice of the Plan Sponsor: 2025 Defined Contribution (DC) Practices. The analysis reveals that DC plan sponsors are placing a growing emphasis on financial wellness and cost efficiency. To that end, many.

BOOT lifts FY26 sales outlook to as high as $2.24B, fueled by e-commerce momentum, new stores, and improving merchandise margins.

TON Strategy Company (TONX) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.9. This compares to a loss of $3.97 per share a year ago.

Ford CEO Jim Farley said he got so humbled by the competition that he realized he needed to overhaul his company or risk falling behind.

Allurion Technologies Inc. ( ALUR ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Tara Brady Shantanu Gaur - Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director Conference Call Participants Joshua Jennings - TD Cowen, Research Division Presentation Operator Hello, and thank you for standing by. My name is Mark, and I will be your conference operator today.

AMD headlined broader growth among the tech-heavy Nasdaq, which advanced 0.1% early Wednesday. Other gains were posted by Qualcomm (up 1.4%), Micron Technology (1.3%), Adobe (0.9%), Nvidia (0.5%), Intel (0.2%) and Amazon (0.2%).

Super Micro Computer (SMCI) stock has declined by close to 30% over the last month, following disappointing quarterly earnings results and margin concerns. However, the stock ought to be on your radar now.

Eli Lilly stock (NYSE: LLY) has surged by 21% this month, driven by strong third-quarter earnings and a favorable obesity drug pricing deal with the U.S. government. However, this recent success doesn't mean the company is invulnerable to challenges.

UnitedHealth Group stock (NYSE: UNH) has declined by 7% over the past month. This downturn is attributed to several significant investor concerns, including rising medical costs within its Medicare Advantage plans, ongoing regulatory and legal scrutiny, and margin pressures in the Optum division.

Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.

Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago.

Evaluate the expected performance of Aramark (ARMK) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Universal Insurance (UVE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Black Diamond (BDTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Crexendo (CXDO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LiveOne (LVO) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.2 per share a year ago.

Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide range of electronics. The greatest detractor from Fund performance for the quarter was Monday.com Ltd.

Baidu's online marketing business is facing a double whammy, with a 15% Q2 decline and a bleak Q3 guide. This is the main story the market is focused on. However, the market is mispricing Baidu as a declining ad business, completely ignoring its rapid and successful transformation into a full-stack AI hyperscaler. Baidu's in-house chip development mirrors Google's and Amazon's, de-risks the business geopolitically, and is already winning billion-RMB contracts.

BlackRock TCP Capital continues to underperform, with a 34.2% share price decline and a 22.2% total return loss over the past year. Despite a high 17.5% dividend yield, TCPC's net investment income and portfolio activity are declining, raising concerns about long-term sustainability. TCPC trades at a historically large 34.56% discount to NAV, reflecting portfolio weakness and negative sentiment in the debt markets.